UTHR
$541.70-5.19%
as of close, Oct 2, 2026
☾ AH $541.70 -5.19%
United Therapeutics CorporationStock · Health CareRussell 1000 0.03%US Stock Market 0.03%Russell 3000 0.03%MSCI World 0.03%MSCI ACWI 0.02%
UTHR — United Therapeutics Corporation price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
100.0150.0200.0250.0300.0350.0400.0450.0500.0550.005.0M$541.70—20162019202120242026
2026-10-02
Price$541.70
MA20$536.45
MA50$487.98
Vol7.5M
Key stats
Price data
- Price
- $541.70
- Change YTD
- +11.17%
- Next earnings
- Nov 4, 2026
- Market cap
- 23.2B
- Enterprise value
- 20.6B
- Shares outstanding
- 42.9M
- 52W low
- $409.07
- 52W high
- $609.35
- From 52W high
- -11.10%
- From 52W low
- +32.42%
- 52W range
- 66%
- Beta
- 0.56
Volume
- Rel volume
- 1.18×
- 30D volume
- 802.5K
- 30D $ vol
- 410.3M
Insider trading
- Insider net 1W
- −$24.3M
- Insider net 1M
- −$99.0M
- Insider net 3M
- −$335.3M
- Insider net 1Y
- −$1.09B
Form 4 transactions by trade date, as filed; latest on file 2026-10-01.
Fundamentals
- Sales (ttm)
- 3.2B
- Sales/share
- $73.55
- EPS (ttm)
- $27.95
- FCF (ttm)
- 1.1B
- FCF/share
- $25.48
- Book value/share
- $149.22
- Net margin
- 41.56%
- ROE
- 20.48%
- ROA
- 18.16%
- Current ratio
- 5.73
Growth (CAGR, ttm) · 10Y
- Sales
- +2.49%+14.32%+14.68%+7.21%
- Net income
- +5.54%+14.57%+22.73%+2.64%
- FCF
- +2.06%+17.51%+14.31%+9.83%
- Shares
- -5.17%-2.96%-0.91%-0.13%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +9.03%+16.50%+22.19%+3.11%
- Sales/share
- +8.08%+17.81%+15.73%+7.35%
- FCF/share
- +7.62%+21.09%+15.36%+9.98%
- Book value/share
- -5.93%+8.98%+12.98%+13.64%
- Price
- +22.18%+34.59%+23.84%+16.45%
- Total return
- +22.18%+34.59%+23.84%+16.45%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 19.4×
- P/OI (ttm)
- 16.6×
- Fwd P/E
- 16.2×
- P/S (ttm)
- 7.4×
- P/B (mrq)
- 3.6×
- P/FCF (ttm)
- 21.3×
- EV/EBITDA (fy)
- 13.8×
- EV/Sales (ttm)
- 6.5×
- FCF yield (ttm)
- 4.70%
- Buyback yield (realized, 1y)
- 5.17%
- Shareholder yield (realized, 1y)
- 5.17%
- Buyback yield (cash, ttm)
- 10.76%
- Shareholder yield (cash, ttm)
- 10.76%
Vs own 10Y history
- P/E
- 87th
- P/OI
- 89th
- P/S
- 98th
- P/B
- 96th
- P/FCF
- 96th
Bar = where today’s multiple sits in UTHR’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-02
1D
-5.19%
5D
+13.93%
1M
+10.10%
3M
-2.56%
YTD
+11.17%
1Y
+22.16%
5Y
+191.39%
Recent filings
- Oct 1Insider sale · ROTHBLATT MARTINE A (Chairperson & CEO · Director) sold 9,500 shares for $5.5M at $560.05–$584.66 under a 10b5-1 plan
- Oct 1Insider sale · MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares for $4.7M at $558.30–$573.15 under a 10b5-1 plan
- Sep 30Insider sale · ROTHBLATT MARTINE A (Chairperson & CEO · Director) sold 9,500 shares for $5.0M at $476.14–$554.70 under a 10b5-1 plan
- Sep 29Insider sale · ROTHBLATT MARTINE A (Chairperson & CEO · Director) sold 9,500 shares for $4.5M at $472.05–$486.77 under a 10b5-1 plan
- Sep 28Insider sale · ROTHBLATT MARTINE A (Chairperson & CEO · Director) sold 9,500 shares for $4.6M at $472.43–$486.01 under a 10b5-1 plan
Financial statements
Open full UTHR financials →Loading financial statements…
Related Health Care
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| NVS | Novartis AG | -13.21% | -0.04% |
| NVO | Novo Nordisk A/S | -20.21% | -0.21% |
| SNY | Sanofi ADS | -10.23% | -1.84% |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | -6.76% | -0.32% |
| NTRA | Natera Inc. | +26.20% | +0.46% |
| ARGX | argenx SE American Depositary Shares | -12.90% | -1.79% |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | -3.09% | +0.00% |
| TEVA | Teva Pharmaceutical Industries Limited American Depositary Shares | +5.44% | +0.56% |
